News Center

Company news

Media reports

27

2021-12

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

Suzhou, December 27, 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatment of COVID 19 infection (NCT04870606).

Picture Name

24

2021-11

Kintor Pharma Receives IND Clearance by NMPA for KX-826’s Pivotal Study to Treat Male Alopecia Patients

Suzhou, November 24, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the IND application for the pivotal study (phase III stage) of pyrilutamide (KX-826), a potential first-in-class drug developed by Kintor Pharma, for the treatment of male androgenetic alopecia (“AGA”) patients was cleared by the National Medical Products Administration (“NMPA”). KX-826 is the first androgen receptor (AR) antagonist which has entered the phase III clinical trial for AGA treatment in China and global.

Picture Name

12

2021-11

Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China

Suzhou, November 12, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical trial of pyrilutamide ("KX-826") in China for the treatment of androgenetic alopecia (AGA) female patients.

Picture Name

09

2021-11

Indonesian Ambassador to China and the Delegation Visited Kintor

In the afternoon of November 8, 2021, Indonesian Ambassador to China, H.E. Djauhari Oratmangun, Indonesian Consul General in Shanghai, Mr. Deny Wachyudi Kurnia, and the Chairman of the Indonesia Chamber of Commercein China, Mr. Liky Sutikno, visited Kintor Pharma for in-depth understanding of the company. The delegation met with founder, Chairman and CEO, Dr. Youzhi Tong and Kintor Pharma’s executives.

Picture Name

03

2021-11

Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors

Suzhou, November 3, 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has enrolled and dosed its first patient with advanced or refractory solid tumors in a clinical trial of ALK-1 antibody (GT90001) in combination with KN046 on November 2 in Taiwan, China.

Picture Name

21

2021-10

Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China

Suzhou, October 21 , 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021.

Picture Name
< 1...101112...23 > proceed page

Kintor